No data to show
XASE
CLDI
Market cap24mUSD
Jul 22, Last price
0.70USD
1D
-2.38%
1Q
44.97%
IPO
-98.58%
Name
First Light Acquisition Group Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-24m
L-18.49%
CFO
-20m
L-27.01%
Profile
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | 45 -89.98% | ||||
Cost of revenue | 21,776 | 30,248 | 23,173 | ||
Unusual Expense (Income) | |||||
NOPBT | (21,776) | (30,248) | (23,128) | ||
NOPBT Margin | |||||
Operating Taxes | (14) | 16 | 11 | ||
Tax Rate | |||||
NOPAT | (21,762) | (30,264) | (23,139) | ||
Net income | (23,814) -18.49% | (29,216) 14.90% | (25,427) -850.78% | ||
Dividends | (1,671) | ||||
Dividend yield | |||||
Proceeds from repurchase of equity | 18,065 | 2,763 | 10,764 | ||
BB yield | |||||
| Debt | |||||
Debt current | 6,925 | 1,923 | 5,541 | ||
Long-term debt | 5,250 | 9,682 | 894 | ||
Deferred revenue | |||||
Other long-term liabilities | 728 | 2,709 | |||
Net debt | 2,584 | 9,326 | 5,963 | ||
| Cash flow | |||||
Cash from operating activities | (19,694) | (26,983) | (13,214) | ||
CAPEX | (585) | (428) | |||
Cash from investing activities | (16) | (478) | (494) | ||
Cash from financing activities | 27,365 | 29,044 | 12,087 | ||
FCF | (23,359) | (67,177) | 18,170 | ||
| Balance | |||||
Cash | 9,591 | 2,049 | 472 | ||
Long term investments | 230 | ||||
Excess cash | 9,591 | 2,279 | 470 | ||
Stockholders' equity | (121,307) | (99,615) | (60,767) | ||
Invested Capital | 132,918 | 101,325 | 25,916 | ||
ROIC | |||||
ROCE | 66.36% | ||||
| EV | |||||
Common stock shares outstanding | 8,005 | 1,689 | 850 | ||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | (20,241) | (28,992) | (22,868) | ||
EV/EBITDA | |||||
Interest | 372 | 1,069 | 158 | ||
Interest/NOPBT | |||||